Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Day (November 2016)
13 slides from Qiagen's investor day presentation, Nov 15, 2016
Slide 1: Bioinformatics: Partner of choice for insights from complex genomic data
Bioinformatics: Partner of choice for insights from complex genomic data Dr. Laura Furmanski, Ph.D. Senior Vice President, Head of Bioinformatics Business Area November 15, 2016 Sample to Insight 2016 Analyst & Investor Day 1
Slide 2: Disclaimer
Disclaimer Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended
Slide 3: Sample to Insight
Sample to Insight 2016 Analyst & Investor Day 3
Slide 4: Recognized for enterprise-grade bioinformatics solutions
Bioinformatics Laura Furmanski Senior Vice President, Business Area Bioinformatics Joined QIAGEN in 2014 Aarhus, Denmark 2015 total sales: ~$45-50 million Redwood City, California ~75% in Academia, Pharma and Applied Testing ~25% in Molecular Diagnostics Waltham, Massachusetts Bioinformatics employe
Slide 5: Customer challenges: Intense pressure to get insights from complex genomic data
Customers face significant challenges with their genomic data Hard to extract Difficulty scaling insights from interpretation increasingly large & and reporting due to complex data skills and turnaround time requirements Lacking skills and Cost base is too high, time to integrate Customer particular
Slide 6: Our ambition: Best suite of products for Life Sciences and Molecular Diagnostics
QIAGEN QIAGEN Core capabilities Life Sciences portfolio Clinical portfolio Microbial Pro Suite IVA Microbial RNA-Seq HGMD Microbial Epigenetics Algorithm development RNA-Seq Explorer QCI-Analyze Services IPA QCI-Interpret Knowledge base Genomics Workbench curation Biomedical Workbench Genomics Serve
Slide 7: Strategy: Increasing focus on Sample to Insight workflows
Push the frontiers of science Delivering cutting-edge bioinformatics solutions Drive Sample to Insight across QIAGEN Supporting differentiated and complete workflows Set new standards for clinical support Advancing the use of genomic data for patients Efficiently scale the bioinformatics portfolio R
Slide 8: Case study: RNA-seq Explorer uncovers causal genes and variants
Case study: RNA-seq Explorer uncovers causal genes and variants Reduce Interpret Unify and time from gene simplify experiment expression tools to report patterns Key challenges Range of applications Data overflow hinders Drug target discovery biological insights Cancer profiling and Integrat
Slide 9: Case study: Microbial Genomics Pro Suite turns microbiomes into insights
Case study: Microbial Genomics Pro Suite turns microbiomes into insights Extraction Inhibitor Amplification Converting data bias removal bias into insight Insight Sample NGS library Data processing preparation interpretation Processing massive Comparative analytics: sample data is not enough Key for
Slide 10: Case study: QIAGEN Clinical Insight is an integral part of GeneReader NGS workflow
Case study: QIAGEN Clinical Insight is an integral part of GeneReader NGS workflow Identify QCI workflow Analyze Review Report variants Full integration for fast and seamless data analysis Easy-to-use analysis tool for clinical researchers Efficient pre-designed data analysis optimized to pane
Slide 11: Case study: the power of QIAGEN Bioinformatics
Case study: the power of QIAGEN Bioinformatics Case study: QCI interpretation time benefits Case study: Cardiology variant classification(1) 90 75% 90 33% reduction in time reduction 80 80 variants of unknown significance 70 70 60 60 Variants 50 50 Hours 40 40 30 30 20 20 10 10 0 0 Manual QCI Interp
Slide 12: 40,000 active users across the QIAGEN bioinformatics product offering
“We truly are a Sample to Insight laboratory. As a “Assembling allele frequency information in a result, we are bringing greater understanding to a comprehensive fashion over many different wide range of important medical issues, particularly populations is a critical element of genome in cancer.” i
Slide 13: Market leader in analysis, interpretation and content
Market leader in analysis, interpretation and content Portfolio with strong commercial traction Solving challenges of complex genomic data Focusing on delivering Sample to Insight solutions Sample to Insight 2016 Analyst & Investor Day 13